INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK CITY, NY / ACCESS Newswire / October 26, 2026 / Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether EyePoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 17, 2026, EyePoint issued a press release "announcing topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals' (REGN) Eylea) was not met in the entire dataset.
On this news, EyePoint's stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026.
Then, on October 19, 2026, EyePoint announced disappointing topline results from its second Phase 3 pivotal clinical trial, LUCIA, evaluating Duravyu for the treatment of wet AMD. The Company disclosed that Duravyu failed to meet its prespecified primary efficacy endpoint of demonstrating statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the standard-of-care control, Regeneron's Eylea (aflibercept). In response to the clinical failure, EyePoint announced significant cost-cutting measures, including the immediate termination of its late-stage wet AMD clinical program and a 53% workforce reduction designed to restructure its operations around separate diabetic macular edema programs.
On this news, EyePoint's stock price fell $2.55 per share, or 85.28%, to close at $0.44 per share on October 19, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP